Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple.
On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab
This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic microangiopathy. oatautta/ After an oral explanation meeting, Omeros stated that the CHMP adopted a negative opinion on the filing. The company plans to request a reconsideration of the opinion and seek assessment by an Ad Hoc Expert Panel, which is an independent group of external clinical and scientific specialists to be assembled by the EMA. Later, on June 26, Brandon Folkes from H.C.
Wainwright cut the price target on Omeros Corp. (NASDAQ:OMER) from $40 to $33, which still implies an adjusted upside of more than 233%. The analyst kept a Buy rating on the stock despite an unfavorable opinion on Yartemlea shared by the CHMP. Folkes labeled this development as a short-term headwind but does not consider this to be a major hurdle for the stock’s long-term potential.